MedTrace Logo

Immunoadsorption Therapy for Patients With Non-Ischemic Dilated Cardiomyopathy (DCM)

NCT01478087 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2013-02-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the clinical safety and feasibility of Mysorba in patients with chronic non-ischemic dilated cardiomyopathy (DCM).

Conditions

  • Cardiomyopathy, Dilated

Interventions

DEVICE

Mysorba

Subjects will undergo one cycle of five immunoadsorption (IA) treatment sessions over two weeks.

Sponsors & Collaborators

  • Asahi Kasei Medical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jeffrey Winters, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01478087 on ClinicalTrials.gov